Log in  First Connection?

Blood CancerArchives

Long non-coding RNAs and survival outcomes in chronic lymphocytic leukemia
Blood Cancer
 1 min.

 Published on 19/05/2026 |  Original article (Full-text)  | Teodora Karan-Djurasevic et al. | Pharmacogenomics 2026; aop:10.1080/14622416.2026.2671918

Chronic lymphocytic leukemia (CLL) is a highly heterogeneous hematological malignancy characterized by pronounced differences in clinical course and genetic . While research has historically focused on alterations in protein-coding genes, it is increasingly evident that the non-coding transcriptome plays...

Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia
Blood Cancer
 1 min.

 Published on 12/05/2026 |  Original article (Full-text)  | Fang Cheng et al. | Haematologica. Volume 111(4).

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder typically managed with BCR::ABL1 tyrosine kinase inhibitors (TKI). However, it can progress from chronic phase (CML-CP) to blast phase (CML-BP), during which BCR::ABL1 kinase domain (KD) genetic variants (e.g., T315I, Y253H) and aberrant...

Asparaginase activity levels and toxicity in children and adolescents with acute lymphoblastic leukemia
Blood Cancer
 1 min.

 Published on 05/05/2026 |  Original article (Full-text)  | Marie-Claude Pelland-Marcotte a et al. | Leukemia & Lymphoma 2026; aop:10.1080/10428194.2026.2656726

Asparaginase (ASP) is a critical treatment component of acute lymphoblastic leukemia (ALL), yet associated with potentially severe complications. We assessed whether serum asparaginase activity (SAA) is associated with development of venous thrombosis, acute pancreatitis, bleeding and/or hypersensitivity...

Importance of five membered heterocyclic compounds in treatment of chronic myeloid leukemia by targeting various pathways
Blood Cancer
 1 min.

 Published on 28/04/2026 |  Original article (Full-text)  | Raju Ninave et al. | Future Medicinal Chemistry 2026; aop:10.1080/17568919.2026.2658831

Chronic myeloid leukemia (CML) is a clonal hematopoietic malignancy characterized by the presence of the Philadelphia chromosome, which generates the constitutively active BCR::ABL1 tyrosine kinase, driving uncontrolled myeloid proliferation. Although BCR::ABL1-targeted tyrosine kinase inhibitors (TKIs)...

Single-cell technologies in deciphering drug resistance of multiple myeloma: mechanistic insights and clinical translation prospects
Blood Cancer
 1 min.

 Published on 21/04/2026 |  Original article (Full-text)  | Jun Wu a * et al. | Leukemia & Lymphoma 2026; 67(6): 1231-1246

The greatest hindrance to long-lasting remission in multiple myeloma (MM) is drug resistance and is modulated by the complex interaction of tumor-intrinsic plasticity and microenvironmental co-evolution. Multi-omics of single cells has transformed the exploration of this complexity, and has solved the...